Skip to main content
. Author manuscript; available in PMC: 2018 Jun 10.
Published in final edited form as: J Control Release. 2017 Mar 31;255:12–26. doi: 10.1016/j.jconrel.2017.03.389

Figure 8.

Figure 8

Ternary DB4-PDB12 si-NPs improve pharmacokinetics and bioactivity of siRNA relative to binary PDB si-NPs after i.v. administration. (A) Ternary si-NPs have increased resilience to disassembly by polyanionic heparin in saline solution. (B) Biodistribution of si-NPs after i.v. administration (1 mg/kg Cy5-labeled dsDNA). Ternary si-NPs have significantly reduced concentration in the kidneys compared to parent PDB si-NPs in male CD-1 mice (n = 6; p < 0.001). (C) Ternary si-NPs persist longer in blood (n ≥ 3; p = 0.008) and (D) increase uptake into orthotopic breast tumors after i.v. administration relative to PDB binary si-NPs (n = 6; p = 0.03). (E) Treatment with 2 doses (0 and 24 h) at 1 mg/kg siRNA silences the model gene luciferase in luciferase-expressing orthotopic MDA-MB-231 xenografts and arrests growth in luminescence signal. DB4-PDB12 si-NPs enhance siRNA bioactivity over parent PDB binary si-NPs (n ≥ 5; p = 0.05).